839 related articles for article (PubMed ID: 24147647)
1. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
[TBL] [Abstract][Full Text] [Related]
2. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan.
Cady RK; Vause CV; Ho TW; Bigal ME; Durham PL
Headache; 2009 Oct; 49(9):1258-66. PubMed ID: 19788468
[TBL] [Abstract][Full Text] [Related]
3. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
Bellamy JL; Cady RK; Durham PL
Headache; 2006 Jan; 46(1):24-33. PubMed ID: 16412148
[TBL] [Abstract][Full Text] [Related]
4. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
5. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine.
Cernuda-Morollón E; Martínez-Camblor P; Ramón C; Larrosa D; Serrano-Pertierra E; Pascual J
Headache; 2014 Jun; 54(6):987-95. PubMed ID: 24673487
[TBL] [Abstract][Full Text] [Related]
6. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
7. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
[TBL] [Abstract][Full Text] [Related]
8. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.
Cady RK; Schreiber CP; Porter JA; Blumenfeld AM; Farmer KU
Headache; 2011 Jan; 51(1):21-32. PubMed ID: 21070228
[TBL] [Abstract][Full Text] [Related]
9. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine.
Cernuda-Morollón E; Larrosa D; Ramón C; Vega J; Martínez-Camblor P; Pascual J
Neurology; 2013 Oct; 81(14):1191-6. PubMed ID: 23975872
[TBL] [Abstract][Full Text] [Related]
10. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.
Mathew NT; Jaffri SF
Headache; 2009; 49(10):1466-78. PubMed ID: 19912346
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic migraine: a 3-month comparator study of naproxen sodium vs SumaRT/Nap.
Cady R; Nett R; Dexter K; Freitag F; Beach ME; Manley HR
Headache; 2014 Jan; 54(1):80-93. PubMed ID: 24020994
[TBL] [Abstract][Full Text] [Related]
12. The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.
Moskatel LS; Graber-Naidich A; He Z; Zhang N
Headache; 2024 Feb; 64(2):188-194. PubMed ID: 37882379
[TBL] [Abstract][Full Text] [Related]
13. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine.
Cernuda-Morollón E; Ramón C; Martínez-Camblor P; Serrano-Pertierra E; Larrosa D; Pascual J
Pain; 2015 May; 156(5):820-824. PubMed ID: 25735000
[TBL] [Abstract][Full Text] [Related]
14. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
[TBL] [Abstract][Full Text] [Related]
15. SumaRT/Nap vs naproxen sodium in treatment and disease modification of migraine: a pilot study.
Cady R; O'Carroll P; Dexter K; Freitag F; Shade CL
Headache; 2014 Jan; 54(1):67-79. PubMed ID: 24021029
[TBL] [Abstract][Full Text] [Related]
16. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC
Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721
[TBL] [Abstract][Full Text] [Related]
17. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
18. Sensory neuropeptides (substance P, calcitonin gene-related peptide) and vasoactive intestinal polypeptide in human saliva: their pattern in migraine and cluster headache.
Nicolodi M; Del Bianco E
Cephalalgia; 1990 Feb; 10(1):39-50. PubMed ID: 1690601
[TBL] [Abstract][Full Text] [Related]
19. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD
Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
[TBL] [Abstract][Full Text] [Related]
20. Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients.
Eren OE; Gaul C; Peikert A; Gendolla A; Ruscheweyh R; Straube A
Sci Rep; 2020 Jul; 10(1):11382. PubMed ID: 32647152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
